logo
Twitter
Discord
Email
logo
Guardian Pharmacy Services, Inc.

Guardian Pharmacy Services, Inc.

NYSE•GRDN
CEO: Mr. Fred P. Burke
Sector: Healthcare
Industry: Medical - Distribution
Listing Date: 2016-04-21
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.
Contact Information
300 Galleria Parkway SE, Suite 800, Atlanta, GA, 30339, United States
404-810-0089
guardianpharmacy.com
Market Cap
$1.98B
P/E (TTM)
48.3
31.8
Dividend Yield
--
52W High
$37.43
52W Low
$17.78
52W Range
69%
Rank34Top 20.2%
5.1
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Average • 5.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q3 2025 Data

Revenue

$377.43M+20.05%
4-Quarter Trend

EPS

$0.16-108.00%
4-Quarter Trend

FCF

$22.96M-414.94%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine-Month Revenue Growth Nine-month revenue $1.051B USD, up 18.1% driven by $110.0M organic growth and $51.2M from Acquisitions.
Profitability Turnaround Achieved Net income attributable to GPSI $28.3M USD, reversing prior $122.0M loss for nine months ended September 30.
SG&A Expenses Significantly Lower SG&A expenses $165.3M USD, down 35.7% for nine months, driven by reduced share-based compensation recognition.
Strong Operating Cash Flow Operating cash flow provided $65.7M USD for nine months, up $30.0M compared to the corresponding prior period.

Risk Factors

Stock Price Volatility Risk Class A common stock price subject to substantial volatility; future dilution risk exists from conversion schedules and outstanding awards.
Acquisition Contingent Liability Contingent consideration liability stands at $3.35M USD; successful integration of recent acquisitions remains critical for performance.
Legal and Compliance Exposure Exposure to legal proceedings and claims arising in ordinary course of business; legal expenses totaled $4.5M USD for nine months.
Prior Period Comparison Skew Prior period SG&A heavily impacted by $128.0M USD share-based expense from RSU modification, affecting comparability analysis.

Outlook

Targeted Growth Strategy Core growth strategy focuses on increasing resident count via organic expansion and acquiring pharmacies in attractive ALF and BHF sectors.
Sufficient Liquidity Position Existing cash and credit facility expected to meet working capital needs over next 12 months, though capital may be required.
New Accounting Adoption Adopted ASU 2023-07 regarding segment reporting effective January 1, 2024, requiring retrospective application for disclosures.

Peer Comparison

Revenue (TTM)

STAAR Surgical CompanySTAA
$94.91B
+30136.8%
Teladoc Health, Inc.TDOC
$2.53B
-2.4%
Guardian Pharmacy Services, Inc.GRDN
$1.39B
+18.7%

Gross Margin (Latest Quarter)

STAAR Surgical CompanySTAA
82.2%
+17.6pp
Harmony Biosciences Holdings, Inc.HRMY
75.1%
-1.9pp
NovoCure LimitedNVCR
73.2%
-3.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
EWTX$2.43B-16.0-30.6%0.7%
TXG$2.38B-31.8-10.3%8.5%
HRMY$2.11B11.624.9%14.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.7%
Moderate Growth
4Q Net Income CAGR
-6.3%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Mar 25, 2026
|
EPS:$0.27
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 10, 2025|
    Revenue: $377.43M+20.0%
    |
    EPS: $0.16-108.0%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 11, 2025|
    Revenue: $344.33M+14.8%
    |
    EPS: $0.15-11.8%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 12, 2025|
    Revenue: $329.31M+19.6%
    |
    EPS: $0.15-150.0%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 26, 2025|
    Revenue: $1.23B+17.4%
    |
    EPS: $-1.77-553.8%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 12, 2024|
    Revenue: $314.39M+19.7%
    |
    EPS: $-2.00+952.6%
    Miss